Perrigo Company plc (PRGO) Spending and interest coverage
- R&D / revenue · 12 months: Value 2.29%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-27..
- Stock-based compensation / revenue · 12 months: Value 1.14%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-27..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2.29% | Research and development expense / revenue. Period ending 2026-06-27. $95.10M ÷ $4.14B × 100 ≈ 2.29% |
| Stock-based compensation / revenue · 12 months | 1.14% | Share-based compensation / revenue. Period ending 2026-06-27. $47.40M ÷ $4.14B × 100 ≈ 1.14% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 95.10M USD | Research and Development Expense |
| Revenue | 4.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 47.40M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -1.56B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $95.10M | $4.14B | $47.40M | $-1.56B | (m) | 2.29% | 1.14% | (m) | (m) |
| 2026-03-28 | $93.30M | $4.18B | $57.40M | $-1.54B | (m) | 2.23% | 1.37% | (m) | (m) |
| 2025-12-31 | $95.40M | $4.25B | $54.60M | $-1.12B | (m) | 2.24% | 1.28% | (m) | (m) |
| 2025-09-27 | $101.40M | $4.28B | $61.50M | $279.10M | (m) | 2.37% | 1.44% | (m) | (m) |
| 2025-06-28 | $102.50M | $4.33B | $54.20M | $286.90M | (m) | 2.37% | 1.25% | (m) | (m) |
| 2025-03-29 | $109.90M | $4.34B | $60.40M | $215.00M | (m) | 2.54% | 1.39% | (m) | (m) |
| 2024-12-31 | $112.20M | $4.37B | $64.40M | $112.90M | (m) | 2.57% | 1.47% | (m) | (m) |
| 2024-09-28 | $114.00M | $4.39B | $55.10M | $-16.90M | (m) | 2.60% | 1.25% | (m) | (m) |
| 2024-06-29 | $117.60M | $4.43B | $63.90M | $-35.20M | (m) | 2.66% | 1.44% | (m) | (m) |
| 2024-03-30 | $120.40M | $4.56B | $59.50M | $48.20M | (m) | 2.64% | 1.31% | (m) | (m) |
| 2023-12-31 | $122.50M | $4.66B | $68.80M | $151.90M | (m) | 2.63% | 1.48% | (m) | (m) |
| 2023-09-30 | $125.50M | $4.65B | $66.40M | $198.50M | (m) | 2.70% | 1.43% | (m) | (m) |
| 2023-07-01 | $125.60M | $4.63B | $61.10M | $169.50M | (m) | 2.71% | 1.32% | (m) | (m) |
| 2023-04-01 | $124.90M | $4.56B | $53.50M | $105.70M | (m) | 2.74% | 1.17% | (m) | (m) |
| 2022-12-31 | $123.10M | $4.45B | $54.90M | $78.90M | (m) | 2.77% | 1.23% | (m) | (m) |
| 2022-10-01 | $120.80M | $4.40B | $56.60M | $94.60M | (m) | 2.74% | 1.29% | (m) | (m) |
| 2022-07-02 | $118.70M | $4.34B | $58.30M | $499.80M | (m) | 2.73% | 1.34% | (m) | (m) |
| 2022-04-02 | $120.20M | $4.20B | $61.40M | $380.70M | (m) | 2.86% | 1.46% | (m) | (m) |
| 2021-12-31 | $122.00M | $4.14B | $60.10M | $410.40M | (m) | 2.95% | 1.45% | (m) | (m) |
| 2021-10-02 | $180.70M | $5.06B | $64.80M | $251.50M | (m) | 3.57% | 1.28% | (m) | (m) |
| 2021-07-03 | $183.50M | $5.02B | $67.90M | $-108.30M | (m) | 3.65% | 1.35% | (m) | (m) |
| 2021-04-03 | $180.90M | (m) | $67.30M | $80.40M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $177.70M | $5.06B | $58.50M | $115.40M | (m) | 3.51% | 1.16% | (m) | (m) |
| 2020-09-26 | $191.00M | $5.10B | $55.20M | $160.70M | (m) | 3.75% | 1.08% | (m) | (m) |
| 2020-06-27 | $192.40M | $5.07B | $53.90M | $310.60M | (m) | 3.79% | 1.06% | (m) | (m) |
| 2020-03-28 | $189.10M | $5.00B | $56.00M | $248.20M | (m) | 3.78% | 1.12% | (m) | (m) |
| 2019-12-31 | $187.40M | $4.84B | $52.20M | $204.80M | (m) | 3.87% | 1.08% | (m) | (m) |
| 2019-09-28 | $172.60M | $4.71B | $52.00M | $319.20M | (m) | 3.66% | 1.10% | (m) | (m) |
| 2019-06-29 | $172.30M | $4.65B | $43.40M | $142.90M | (m) | 3.70% | 0.93% | (m) | (m) |
| 2019-03-30 | $220.40M | $4.69B | $37.40M | $182.50M | (m) | 4.70% | 0.80% | (m) | (m) |
| 2018-12-31 | $218.60M | $4.73B | $37.70M | $236.50M | (m) | 4.62% | 0.80% | (m) | (m) |
| 2018-09-29 | $220.90M | $4.82B | $42.30M | $287.60M | (m) | 4.58% | 0.88% | (m) | (m) |
| 2018-06-30 | $215.70M | $4.92B | $51.30M | $571.80M | (m) | 4.39% | 1.04% | (m) | (m) |
| 2018-03-31 | $166.30M | $4.97B | $50.40M | $626.00M | (m) | 3.35% | 1.01% | (m) | (m) |
| 2017-12-31 | $167.70M | $4.95B | $43.80M | $598.20M | (m) | 3.39% | 0.89% | (m) | (m) |
| 2017-09-30 | $162.30M | $4.99B | $35.80M | $-45.00M | (m) | 3.25% | 0.72% | (m) | (m) |
| 2017-07-01 | $174.10M | $5.02B | $28.20M | $-1.68B | (m) | 3.46% | 0.56% | (m) | (m) |
| 2017-04-01 | $178.50M | $5.13B | $13.30M | $-1.64B | (m) | 3.48% | 0.26% | (m) | (m) |
| 2016-12-31 | $184.00M | $5.28B | $23.00M | $-2.00B | (m) | 3.48% | 0.44% | (m) | (m) |
| 2016-10-01 | $189.10M | $5.64B | $26.60M | $-1.67B | (m) | 3.35% | 0.47% | (m) | (m) |
| 2016-07-02 | $180.50M | $5.63B | $32.40M | $29.00M | (m) | 3.20% | 0.58% | (m) | (m) |
| 2016-04-02 | (m) | $5.68B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $186.20M | $5.35B | $40.20M | $520.70M | (m) | 3.48% | 0.75% | (m) | (m) |
| 2015-09-26 | $192.80M | $5.00B | $37.10M | $799.10M | (m) | 3.86% | 0.74% | (m) | (m) |
| 2015-06-27 | $187.80M | $4.60B | $31.60M | $747.70M | (m) | 4.08% | 0.69% | (m) | (m) |
| 2015-03-28 | $163.20M | $4.22B | $29.80M | $718.20M | (m) | 3.87% | 0.71% | (m) | (m) |
| 2014-12-27 | $172.50M | $4.17B | $27.20M | $622.30M | (m) | 4.14% | 0.65% | (m) | (m) |
| 2014-09-27 | $156.80M | $4.08B | $27.50M | $524.50M | (m) | 3.84% | 0.67% | (m) | (m) |
| 2014-06-28 | $152.50M | $4.06B | $24.60M | $567.00M | (m) | 3.76% | 0.61% | (m) | (m) |
| 2014-03-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-28 | (m) | $3.70B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-29 | $115.20M | $3.54B | $18.40M | $679.10M | (m) | 3.25% | 0.52% | (m) | (m) |
| 2013-03-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $105.80M | $3.17B | $19.00M | $569.20M | (m) | 3.33% | 0.60% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |